The information contained in this website has been developed by Arcutis Medical Affairs and is intended for US healthcare professionals (HCPs) only.
Explore a collection of congress presentations and published literature from Arcutis.
Safety, efficacy, and pharmacokinetics of roflumilast cream 0.3% once daily for treatment of plaque psoriasis in children aged 2-11 years
Efficacy and safety of roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARRECTOR trial
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: A randomized, double-blind, vehicle-controlled phase 2b study
Efficacy of roflumilast foam 0.3% in patients with seborrheic dermatitis: a double-blind, vehicle-controlled phase 2a randomized clinical trial
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial
Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2)
Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 phase 3 trials
Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus
Patient and healthcare provider perspective on the disease burden of seborrheic dermatitis in the United States: results from a national survey
Patient and healthcare provider perspective on the treatment patterns and patient satisfaction of seborrheic dermatitis in the United States: results from a national survey
Your file will open automatically upon submission.
Fields marked with an asterisk (*) are required.
Arcutis Biotherapeutics, Inc. (“Arcutis”) understands that protecting your personal information is very important. We do not share any personally identifiable information you give us with third parties for their own marketing purposes.
I would like to receive occasional information from Arcutis about products, services, and opportunities that may be of interest to me and agree to allow Arcutis to use the information provided for this purpose. Examples include, but are not limited to, information or opportunities to participate in surveys or provide feedback, and information about clinical trials.
I can opt out at any time by clicking “Unsubscribe” at the bottom of any such communication, calling 805-418-5006, or by sending a letter to Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361.
For additional details, please see Arcutis’ Privacy Policy.
By clicking Download below, I am agreeing to receive the requested information. I further acknowledge the Arcutis Privacy Policy and affirm that I am at least eighteen (18) years of age.
Δ
You are now leaving the Arcutis Medical Affairs website. Arcutis Biotherapeutics is not responsible for the content on these third-party websites.